New combo therapy tested to control returning prostate cancer
NCT ID NCT01786265
Summary
This study is testing whether adding two drugs (abiraterone acetate and prednisone) to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has returned after surgery or radiation. The goal is to keep PSA levels low for longer after the 8-month treatment ends. Researchers are comparing the two approaches in 310 participants to see which provides better long-term control of the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.